BioNTech SE (BNTX) Cash from Discontinued Operations (2019 - 2025)
BioNTech SE (BNTX) posted Cash from Discontinued Operations of 912681309.82 for Q3 2025, up 450.36% on a QoQ basis from 165832094.29 in Q2 2025, and up 230.08% year-over-year from 276506427.74 in Q3 2024.
BioNTech SE (BNTX) has 7 years of Cash from Discontinued Operations data on file, last reported at 912681309.82 in Q3 2025.
- In Q3 2025, Cash from Discontinued Operations rose 230.08% year-over-year to 912681309.82; the TTM figure through Sep 2025 stood at 444345218.02 (down 127.96% YoY), while the FY2022 annual figure was 13852306577.58, up 1261.02% from the prior year.
- Cash from Discontinued Operations advanced to 912681309.82 in Q3 2025, from 165832094.29 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 4776784629.94 in Q2 2023 and bottomed at 821206181.94 in Q1 2025.
- A 5-year average of 1099281235.09 and a median of 537105660.03 in 2021 frame the typical range for Cash from Discontinued Operations.
- Annual changes were most pronounced in 2022 — Cash from Discontinued Operations jumped 1210566204.64% — and 2024, when it tumbled 179.46%.
- Year by year, Cash from Discontinued Operations stood at 228222204.75 in 2021, then soared by 270.69% to 845989115.3 in 2022, then climbed by 4.38% to 883064594.77 in 2023, then sank by 179.46% to 701652440.19 in 2024, then surged by 230.08% to 912681309.82 in 2025.
- The last three Cash from Discontinued Operations figures came in at 912681309.82 (Q3 2025), 165832094.29 (Q2 2025), and 821206181.94 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 912.68 Mn |
| Sep 30, 2025 | 912.68 Mn |
| Jun 30, 2025 | 165.83 Mn |
| Jun 30, 2025 | 165.83 Mn |
| Mar 31, 2025 | -821.21 Mn |
| Mar 31, 2025 | -821.21 Mn |
| Sep 30, 2024 | -701.65 Mn |
| Sep 30, 2024 | -701.65 Mn |
| Jun 30, 2024 | 1.75 Bn |
| Jun 30, 2024 | 1.75 Bn |
| Mar 31, 2024 | -344.70 Mn |
| Mar 31, 2024 | -344.70 Mn |
| Sep 30, 2023 | 883.06 Mn |
| Sep 30, 2023 | 883.06 Mn |
| Jun 30, 2023 | 4.78 Bn |
| Jun 30, 2023 | 4.78 Bn |
| Mar 31, 2023 | -727.08 Mn |
| Mar 31, 2023 | -727.08 Mn |
| Dec 31, 2022 | 845.99 Mn |
| Dec 31, 2022 | 845.99 Mn |
| Jun 30, 2022 | 4.18 Bn |
| Jun 30, 2022 | 4.18 Bn |
| Mar 31, 2022 | 4.55 Bn |
| Mar 31, 2022 | 4.55 Bn |
| Dec 31, 2021 | 228.22 Mn |
| Dec 31, 2021 | 228.22 Mn |
| Sep 30, 2021 | 1.77 Bn |
| Sep 30, 2021 | 1.77 Bn |
| Jun 30, 2021 | 120.79 Mn |
| Jun 30, 2021 | 120.79 Mn |
| Mar 31, 2021 | 375.50 |
| Mar 31, 2021 | 375.50 |
| Dec 31, 2020 | 297.12 |
| Dec 31, 2020 | 297.12 |
| Sep 30, 2020 | 224.85 Mn |
| Sep 30, 2020 | 224.85 Mn |
| Jun 30, 2020 | 17.07 Mn |
| Jun 30, 2020 | 17.07 Mn |
| Mar 31, 2020 | 60.39 Mn |
| Mar 31, 2020 | 60.39 Mn |
| Dec 31, 2019 | -149.33 Mn |
| Dec 31, 2019 | -149.33 Mn |
| Sep 30, 2019 | 54.77 Mn |
| Sep 30, 2019 | 54.77 Mn |
| Jun 30, 2019 | 61.21 Mn |
| Jun 30, 2019 | 61.21 Mn |
| Mar 31, 2019 | 35.48 Mn |
| Mar 31, 2019 | 35.48 Mn |